Hot topic

A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing.

Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O; SAKK.

J Thorac Oncol. 2016 Jun 13. pii: S1556-0864(16)30507-X. doi: 10.1016/j.jtho.2016.05.032. [Epub ahead of print]

Kommentar schreiben

Kommentare: 0